Good morning, everyone, and welcome to another working week. We hope the weekend was refreshing because the time has come to resume that familiar routine of meetings and deadlines and what-not. Of course, the spot of rain falling this morning in our region does not make it easier. To cope, please join us as we grab a cup of stimulation and dig in. Hope you have a wonderful day... Topping the news this morning, . , .  writes. The $24.50 per share price Merck has agreed to pay is more than three times the Idenix closing price last week. Idenix has filed lawsuits claiming the controversial Gilead drug called Sovaldi infringes on its patents, although Merck is also embroiled in a patent suit with Gilead.